Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) — Capital Reinvestment Ratio
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has a Capital Reinvestment Ratio of 0.25x as of June 2023, meaning it reinvests 0% of its operating cash flow (€2.10 Billion) in capital expenditures (€524.46 Million). Check tangible net worth ratio of Guangzhou Baiyunshan Pharmaceutical Hold to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Capital Reinvestment Ratio (2013–2024)
This chart tracks Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see GU5 operating cash flow.
Annual Capital Reinvestment Ratio for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2024)
Year-by-year Capital Reinvestment Ratio for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2024. See free cash flow generation of Guangzhou Baiyunshan Pharmaceutical Hold to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.33x | €3.44 Billion | €1.13 Billion | ▼ -17.4% |
| 2023 | 0.40x | €4.10 Billion | €1.63 Billion | ▲ +100.7% |
| 2022 | 0.20x | €7.00 Billion | €1.38 Billion | ▼ -10.6% |
| 2021 | 0.22x | €5.67 Billion | €1.25 Billion | ▼ -85.2% |
| 2020 | 1.50x | €585.19 Million | €876.50 Million | ▲ +213.5% |
| 2019 | 0.48x | €5.02 Billion | €2.40 Billion | ▲ +420.8% |
| 2018 | 0.09x | €5.22 Billion | €478.62 Million | ▼ -14.5% |
| 2017 | 0.11x | €1.83 Billion | €196.77 Million | ▲ +19.8% |
| 2016 | 0.09x | €2.54 Billion | €228.03 Million | ▼ -66.2% |
| 2015 | 0.27x | €1.94 Billion | €515.34 Million | ▲ +30.1% |
| 2014 | 0.20x | €1.75 Billion | €356.70 Million | ▼ -22.2% |
| 2013 | 0.26x | €1.34 Billion | €350.35 Million | — |